ABI-009

PreclinicalSmall molecule

Bristol-Myers Squibb

ABI-009 is one of 2 small molecule programs targeting PEComa. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PecomaActive, not recruiting

PecomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Pecoma

#DrugCompanyPhaseTrials

Rapamune

PPrism Pharmaceuticals

ABI-009

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

PEComa1 trial

Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation

Approved for marketing·AAadi Bioscience, Inc.··NCT03817515

Hematologic Malignancies1 trial

ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00635284·27 enrolled

Multiple Myeloma1 trial

Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Withdrawn·MMassachusetts General Hospital·Phase 1·NCT03657420

Epilepsy1 trial

ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE)

Completed·SSeattle Children's Hospital·Phase 1·NCT03646240·14 enrolled

Neuroendocrine Tumors1 trial

A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System

Terminated·RRobert Ramirez·Phase 2·NCT03670030·5 enrolled

2 more indications

Acute Lymphoblastic Leukemia1 trial

ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome

Withdrawn·AAadi Bioscience, Inc.·Phase 2·NCT03747328

Bladder Cancer1 trial

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

Completed·AAadi Bioscience, Inc.·Phase 1/2·NCT02009332·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for ABI-009. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABI-009 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABI-009. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Bristol-Myers Squibb

ABI-009

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

PEComa1 trial

Hematologic Malignancies1 trial

Multiple Myeloma1 trial

Epilepsy1 trial

Neuroendocrine Tumors1 trial

Acute Lymphoblastic Leukemia1 trial

Bladder Cancer1 trial

References

Drug Info

Quick Facts

Related News